Vaccines
The world urgently needs 20 billion doses of a vaccine that will protect global citizens against the coronavirus. States are throwing huge sums of public money at the race to beat Covid-19, but who will get there first? Will Big Pharma focus on private profit? Will vaccine nationalism prevail, or will the patent be shared to create a low-cost global supply?
Mayo 2020
The world urgently needs 20 billion doses of a vaccine that will protect global citizens against the coronavirus. States are throwing huge sums of public money at the race to beat Covid-19, but who will get there first? Will Big Pharma focus on private profit? Will vaccine nationalism prevail, or will the patent be shared to create a low-cost global supply?
Big Pharma, one of the most lucrative industries in the world, does not usually give priority to vaccine development, as it is financially risky and other drugs are more profitable.
The public spends billions to help with the research and development of commercial drugs, but usually only a fraction of this amount goes to fund vaccine development.
The Coronavirus has turned the tables: The stepchild of the drug industry now gets full attention – and huge public funding.
The reporters of Investigate Europe followed the public money spent on the hunt for a Covid-19 vaccine and found that most of these grants and loans are given without the necessary conditions to ensure global supply and a fair access. If too little is done to prevent “vaccine nationalism,” in the end the public will pay the price.
Web Exclusives
Explainer
Publicaciones
Ue, i conflitti d’interessi dei negoziatori dei vaccini
Il Fatto Quotidiano, Italy
6 noviembre 2022
Οι Μυστικοί Εφτά και ο αρχιλομπίστας της Big Pharma
EfSyn, Greece
5 abril 2022
Vacinas covid: quem são os negociadores secretos da UE com a indústria farmacêutica?
Público, Portugal
8 noviembre 2021
EU’s ‘secret’ vaccine negotiators: Who’s dealing with Big Pharma?
EUobserver, Belgium
4 noviembre 2021
Anonym im Namen der EU
taz, Germany
4 noviembre 2021
„Diese Preise zahlen wir nicht“: Einblicke in die streng geheimen Verhandlungen zwischen EU und „Big Pharma“
Der Tagesspiegel, Germany
24 septiembre 2021
EU negotiators defend high Covid vaccines prices paid to pharma
EUobserver, Belgium
23 septiembre 2021
Dyrt å få vaksiner først
Klassekampen, Norway
23 septiembre 2021
Colpo grosso Big Pharma: intascati 31 mld in più
Il Fatto Quotidiano, Italy
23 septiembre 2021
A UE cedeu às exigências das farmacêuticas em negociações secretas sobre o preço das vacinas
Público, Portugal
23 septiembre 2021
Jak Europa lawirowała w sprawie patentów na szczepionki: wspierać USA czy Big Pharmę?
Gazeta Wyborcza, Poland
10 mayo 2021
Quebra de patentes de vacinas: EUA e Espanha de um lado, Portugal e Alemanha do outro
Público, Portugal
10 mayo 2021
Εμβόλια Covid-19: υποκρισία με (ευρωπαϊκή) πατέντα
EfSyn, Greece
10 mayo 2021
Защо ЕС блокира предложение, което ще разшири значително производството на ваксини?
Baricada Bulgaria, Bulgaria
24 marzo 2021
Europa blochează decizia care ar extinde masiv capacitatea de producție a vaccinului anti-covid. De ce?
Baricada Bulgaria, Bulgaria
19 marzo 2021
Europa stanser grep som kan skaffe mye mer covid-19-vaksine
Stavanger Aftenblad, Norway
10 marzo 2021
Ble maktesløst vitne til død – selv om vaksinen fantes
NRK, Norway
28 agosto 2020
Norge dropper globalt vaksinekjøp
NRK, Norway
28 agosto 2020
Les Etats européens sont pour l’instant incapables de garantir un accès équitable à un futur vaccin contre le Covid
Basta!, France, Basta!
22 julio 2020
Szczepionka na koronawirusa będzie dostępna dla Polaków? Może być z tym kłopot…
Newsweek Poland, Poland
28 mayo 2020
Wer bekommt den Impfstoff – und zu welchem Preis?
Republik, Switzerland
21 mayo 2020
Globaler Wettkampf um ein Mittel gegen Covid-19: Die streng geheimen Fördermittel für den Coronavirus-Impfstoff
Der Tagesspiegel, Germany
21 mayo 2020
Die Jagd nach der ersten Spritze
Falter, Austria
20 mayo 2020
Vaccini, egoismo e guerra tra gli Stati
Il Fatto Quotidiano, Italy
18 mayo 2020
A vaccine for all may be an (expensive) chimera
Público, Portugal
17 mayo 2020